Skip to main content
All lobbying filings

JEFFREY J. KIMBELL & ASSOCIATES, INC.

JEFFREY J. KIMBELL & ASSOCIATES, INC. filed a Q3 report for CATALYST PHARMACEUTICALS on October 17, 2026, reporting $30,000 in lobbying income.

Lobbying for CATALYST PHARMACEUTICALS · Pharmaceutical Company.

All filings by JEFFREY J. KIMBELL & ASSOCIATES, INC. · Everything CATALYST PHARMACEUTICALS has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$30,000
What the client paid this registrant for the period.
Client based in
Florida

Official filing document

 Lobbyists on this filing 6
  • JOHN R RAY
    Previously held: Legislative Assistant, Rep. Mike Kelly
  • KEITH STUDDARD
    Previously held: Legislative Director, Rep. Marsha Blackburn
  • JOHN HERZOG
    Previously held: Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President
  • LAURA KEMPER
    Previously held: Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services
  • BRETT MEEKS
    Previously held: Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander
  • KRISTIN FRITSCH
    Previously held: Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

General FDA issues related to orphan drugs

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem